Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
effi ciently with cancer cell proliferation and/or survival in<br />
a bone environment in the absence of androgens. The lead<br />
compounds will be tested for their effi cacy in models for<br />
bone metastatic prostate cancer. Hence, the translation of<br />
the obtained knowledge into therapeutic strategies is an<br />
integrated part of the project.<br />
Expected results<br />
We expect to identify 3-5 novel targets that will be pursued<br />
for the utility in high-throughput screens of low molecular<br />
weight compounds. We expect to identify 2-3 molecules<br />
that can be tested in an animal model for bone metastatic<br />
prostate cancer.<br />
Potential applications<br />
Treatment of metastatic prostate cancer. Based on the animal<br />
models a decision will be made for animal toxicological testing<br />
(beyond the scope of this IP) and phase 1 clinical trials.<br />
The consortium will start a joint venture with a pharmaceutical<br />
company.<br />
Coordinator<br />
J. A. Schalken<br />
Radboud University Nijmegen<br />
Medical Center<br />
Dept. of Urology<br />
Nijmegen, The Netherlands<br />
primaproject@uro.umcn.nl<br />
Partners<br />
Jan Trapman<br />
Erasmus Medical Center<br />
Rotterdam, The Netherlands<br />
Bohdan Wasylyk<br />
Centre Européen de Recherche<br />
en Biologie et Médecine<br />
Strasbourg, France<br />
Freddie Hamdy<br />
University of Sheffield<br />
Sheffield, United Kingdom<br />
Olli Kallioniemi<br />
University of Turku<br />
VTT Technical <strong>Research</strong> Centre<br />
Turku, Finland<br />
BIOLOGY<br />
Johan Tijhuis<br />
COMPOUND Handling BV<br />
Nijmegen, The Netherlands<br />
Zoran Culig<br />
Medizinische Universität Innsbruck<br />
Innsbruck, Austria<br />
Craig Robson<br />
University of Newcastle upon Tyne<br />
Newcastle upon Tyne, United Kingdom<br />
Andrew Cato<br />
Forschungszentrum Karlsruhe GMBH<br />
Karlsruhe, Germany<br />
George Thalmann<br />
Universität Bern<br />
Bern, Switzerland<br />
Norman James Maitland<br />
University of York<br />
York, United Kingdom<br />
Olivier Cussenot<br />
Centre de Recherche pour<br />
les pathologies prostatiques<br />
Paris, France<br />
Gabri van der Pluijm<br />
Leiden University Medical Center<br />
Leiden, The Netherlands<br />
Tapio Visakorpi<br />
University of Tampere<br />
Tampere, Finland<br />
Varda Rotter<br />
Weizmann Institute of Science<br />
Rehovot, Israel<br />
David Neal<br />
The Chancellor, Master and Scholars<br />
of the University of Cambridge<br />
Cambridge, United Kingdom<br />
Project number<br />
LSH-CT-2004-504587<br />
EC contribution<br />
€ 6 000 000<br />
Duration<br />
60 months<br />
Starting date<br />
01/07/2004<br />
Instrument<br />
IP<br />
Project website<br />
www.primaproject.org<br />
67
Change language